Literature DB >> 8601097

Long term adjuvant therapy for primary breast cancer.

R D Bulbrook.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8601097      PMCID： PMC2350071          DOI： 10.1136/bmj.312.7028.389

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  6 in total

1.  Results of the Cancer Research Campaign Adjuvant Trial for Perioperative Cyclophosphamide and Long-Term Tamoxifen in Early Breast Cancer reported at the tenth year of follow-up. Cancer Research Campaign Breast Cancer Trials Group.

Authors:  M Baum; J Houghton; D Riley
Journal:  Acta Oncol       Date:  1992       Impact factor: 4.089

2.  Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group.

Authors:  L E Rutqvist; H Johansson; T Signomklao; U Johansson; T Fornander; N Wilking
Journal:  J Natl Cancer Inst       Date:  1995-05-03       Impact factor: 13.506

3.  Node-negative minimal invasive breast cancer patients are not candidates for routine systemic adjuvant therapy.

Authors:  D Rosner; W W Lane
Journal:  Cancer       Date:  1990-07-15       Impact factor: 6.860

4.  Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up.

Authors:  P P Rosen; S Groshen; D W Kinne; L Norton
Journal:  J Clin Oncol       Date:  1993-11       Impact factor: 44.544

5.  Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

Authors:  T J Powles; T Hickish; J A Kanis; A Tidy; S Ashley
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

Review 6.  A risk-benefit assessment of tamoxifen therapy.

Authors:  W H Catherino; V C Jordan
Journal:  Drug Saf       Date:  1993-05       Impact factor: 5.606
  6 in total
  8 in total

Review 1.  Management of primary breast cancer.

Authors:  A Melville; A Liberati; R Grilli; T Sheldon
Journal:  Qual Health Care       Date:  1996-12

2.  Adjuvant treatment with tamoxifen. Informed consent and follow up in aTTom trial are inadequate.

Authors:  H Cunningham
Journal:  BMJ       Date:  1996-08-24

3.  Adjuvant treatment with tamoxifen. Care is necessary.

Authors:  R D Bulbrook
Journal:  BMJ       Date:  1996-08-24

4.  Adjuvant treatment with tamoxifen. Local research ethics committees should review their approval of prevention trial.

Authors:  C Read
Journal:  BMJ       Date:  1996-04-20

5.  Adjuvant treatment with tamoxifen. Recruitment into studies assessing optimum duration of treatment must continue.

Authors:  H Earl; P Baker; D Kerr; M Lee; R Gray; M Baum
Journal:  BMJ       Date:  1996-04-20

6.  Adjuvant treatment with tamoxifen. Side effects may have been overstated.

Authors:  M Baum; J Cuzick
Journal:  BMJ       Date:  1996-04-20

7.  Adjuvant treatment with tamoxifen. Clinicians must share knowledge with their patients more readily.

Authors:  H Goodare
Journal:  BMJ       Date:  1996-04-20

8.  Adjuvant treatment with tamoxifen. Multicentre trial should be welcomed.

Authors:  A P Corder
Journal:  BMJ       Date:  1996-04-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.